Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
Antioxidant balance can influence overall skin clarity and tone
Its active component (Ac-LKKTETQ) is a thymosin 4 fragment identified in analytical and anti-doping studies
The glutathione molecule is too large to penetrate deep into the skin on its own
Retatrutide An emerging triple agonist (GLP1, GIP, and glucagon receptors) currently under active study and not FDA-approved for weight loss or general wellness
US$ 26.91
US$ 25.90
US$ 25.47
US$ 26.89
US$ 22.11
US$ 27.60
US$ 27.52
US$ 23.67
US$ 27.41
&srotate=0)
